Success Metrics

Clinical Success Rate
50.0%

Based on 4 completed trials

Completion Rate
50%(4/8)
Active Trials
2(20%)
Results Posted
75%(3 trials)
Terminated
4(40%)

Phase Distribution

Ph phase_3
1
10%
Ph phase_4
1
10%
Ph phase_2
6
60%
Ph phase_1
2
20%

Phase Distribution

2

Early Stage

6

Mid Stage

2

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
2(20.0%)
Phase 2Efficacy & side effects
6(60.0%)
Phase 3Large-scale testing
1(10.0%)
Phase 4Post-market surveillance
1(10.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

50.0%

4 of 8 finished

Non-Completion Rate

50.0%

4 ended early

Currently Active

2

trials recruiting

Total Trials

10

all time

Status Distribution
Active(2)
Completed(4)
Terminated(4)

Detailed Status

Terminated4
Completed4
Recruiting1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
2
Success Rate
50.0%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (20.0%)
Phase 26 (60.0%)
Phase 31 (10.0%)
Phase 41 (10.0%)

Trials by Status

terminated440%
recruiting110%
active_not_recruiting110%
completed440%

Recent Activity

2 active trials
Showing 5 of 10
recruitingphase_2

Oral Bevacizumab-800CW and Cetuximab-800CW Administration to Detect Early Esophageal Adenocarcinomas

NCT05745857
completedphase_1

A Phase I Comparative Study of Pharmacokinetics, Safety, and Efficacy of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma

NCT07435311
active_not_recruitingphase_3

A Comparative Study of Efficacy and Safety of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma

NCT07435324
completedphase_4

Skin Changes in Head and Neck Cancer During Immuno-(Chemo-) And Radiotherapy With Erbitux® (HICARE)

NCT01553032
completedphase_2

Chemoradiotherapy in Stage III Non-small Cell Lung Cancer (NSCLC)

NCT01102231
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT05745857Phase 2

Oral Bevacizumab-800CW and Cetuximab-800CW Administration to Detect Early Esophageal Adenocarcinomas

Recruiting
NCT07435311Phase 1

A Phase I Comparative Study of Pharmacokinetics, Safety, and Efficacy of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma

Completed
NCT07435324Phase 3

A Comparative Study of Efficacy and Safety of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma

Active Not Recruiting
NCT01553032Phase 4

Skin Changes in Head and Neck Cancer During Immuno-(Chemo-) And Radiotherapy With Erbitux® (HICARE)

Completed
NCT01102231Phase 2

Chemoradiotherapy in Stage III Non-small Cell Lung Cancer (NSCLC)

Completed
NCT00570674Phase 1

Abraxane in Combination With Carboplatin, Erbitux and IMRT for Locally Advanced Squamous Cancer of the Head and Neck

Terminated
NCT01237483Phase 2

Reirradiation and Erbitux in the HNSCC

Completed
NCT01794845Phase 2

Cetuximab + Taxotere With Low Dose Fractionated Radiation for Head and Neck Carcinoma

Terminated
NCT00681876Phase 2

Phase II Study of Avastin + Erbitux + Irinotecan as 2nd Line Treatment of Colorectal Cancer

Terminated
NCT00518193Phase 2

Phase II Study , Association of Cisplatine Topotecan and Cetuximab in Patients Whith Late or in Progress Epithelial Cancer of the Cervix

Terminated

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10